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Abstract 
Despite significant therapeutic advances in heart failure (HF) therapy, the morbidity and 
mortality associated with this disease remains unacceptably high. The concept of metabolic 
dysfunction as an important underlying mechanism in HF is well established.  
Cardiac function is inextricably linked to metabolism, with dysregulation of cardiac metabolism 
pathways implicated in a range of cardiac complications, including HF. Modulation of cardiac 
metabolism has therefore become an attractive clinical target. Cardiac metabolism is based on 
the integration of adenosine triphosphate (ATP) production and utilization pathways. ATP itself 
impacts the heart not only by providing energy, but also represents a central element in the 
purinergic signaling pathway, which has received considerable attention in recent years. 
Furthermore, novel drugs that have received interest in HF include angiotensin receptor blocker-
neprilysin inhibitor (ARNi) and sodium glucose cotransporter 2 (SGLT-2) inhibitors, whose 
favorable cardiovascular profile has been at least partly attributed to their effects on metabolism. 
This review, describes the major metabolic pathways and concepts of the healthy heart 
(including fatty acid oxidation, glycolysis, Krebs cycle, Randle cycle, and purinergic signaling) 
and their dysregulation in the progression to HF (including ketone and amino acid metabolism). 
The cardiac implications of HF comorbidities, including metabolic syndrome, diabetes mellitus 
and cachexia are also discussed. Finally, the impact of current HF and diabetes therapies on 
cardiac metabolism pathways and the relevance of this knowledge for current clinical practice is 
discussed. Targeting cardiac metabolism may have utility for the future treatment of patients 
with HF, complementing current approaches.  
Keywords (5): cardiac metabolism; heart failure; insulin resistance; metabolic therapy; 
purinergic signaling 
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ADHF acute decompensated heart failure 
ANP atrial natriuretic peptide 
ARNi angiotensin receptor blocker-neprilysin inhibitor 
ATP adenosine triphosphate 
BCAA branched chain amino acid 
hCPT-1 carnitine palmitoyltransferase-1 
CHF chronic heart failure 
CV cardiovascular 
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DM diabetes mellitus 
HF heart failure 
HFrEF HF with reduced ejection fraction 
FAO fatty acid oxidation 
FA fatty acids 
FFA free FA 
GLP-1RA glucagon-like peptide-1 receptor agonist 
IR insulin resistance 
LVEF left ventricular ejection fraction 
MetS metabolic syndrome 
MI myocardial infarction 
NPs natriuretic peptides 
NYHA New York Heart Association 
PDH pyruvate dehydrogenase 
PFox partial fatty-acid oxidation 
PPARs peroxisome proliferator-activated receptor agonists 
RAAS renin–angiotensin–aldosterone system 
SGLT-2 sodium glucose cotransporter-2 
TCA tricarboxylic acid 
TZDs thiazolidinediones 
TMZ trimetazidine  
 
1. INTRODUCTION  
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Heart failure (HF) is associated with a significant health burden with an estimated prevalence of 
62 million patients worldwide(Benjamin, et al., 2017). Despite recent advances in HF therapies, 
the 5-year mortality rate continues to increase (Benjamin, et al., 2017). Current therapeutic 
approaches for HF target the neurohumoral systems and include the renin angiotensin 
aldosterone system and/or the β- adrenergic receptor signaling pathway, mineralocorticoid 
receptor antagonists, inotropes, diuretics, and mechanical devices (Ponikowski, et al., 2016). 
However, they do not sufficiently address the ‘metabolic nature’ of the heart. 
 
Metabolic failure is considered to play a central role in the pathogenesis of HF (Neubauer, 2007). 
There is growing evidence that patients with HF exhibit disturbances in myocardial energy 
substrate metabolism, resulting in the progression and worsening of disease (Bertero & Maack, 
2018; Stanley, Recchia, & Lopaschuk, 2005). Moreover, the role of adenosine triphosphate 
(ATP) as an extracellular signaling molecule in cardiovascular (CV) pathophysiology and its 
therapeutic potential in cardiac diseases have invoked significant interest recently and are 
discussed in a number of detailed reviews (Burnstock, 2006, 2007a, 2017). 
 
Novel metabolic therapies to target cardiac metabolism have the potential to improve patient 
outcomes (Greene, et al., 2016; Wende, Brahma, McGinnis, & Young, 2017). This review aims 
to discuss the pivotal role of cardiac metabolism at all stages of HF (early, mid and advanced), 
the role of purine nucleosides and nucleotides as extracellular signaling molecules in the disease, 
and the effects of therapies approved for the treatment of HF (or associated co-morbidities) on 
cardiac metabolism, including its relevance for clinical practice. Finally, the concept of 
‘resetting’ metabolic pathways as an important therapeutic option in HF is discussed. 
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2. CARDIAC METABOLISM IN HEALTH AND DISEASE 
2.1 Metabolic pathways in the healthy heart 
The normal adult heart obtains 60–100% of its ATP supply from fatty acid oxidation (FAO) 
(Stanley, Lopaschuk, Hall, & McCormack, 1997; Wisneski, Stanley, Neese, & Gertz, 1990). 
Mitochondrial oxidation of fatty acids (FAs) consumes more O2 per molecule of ATP produced 
than most other sources of fuel, making FAs the less efficient substrate for energy production 
(Lopaschuk, Ussher, Folmes, Jaswal, & Stanley, 2010). Glucose metabolism exhibits a greater 
fuel efficiency, providing 40% more ATP per O2 molecule. FAs are thus the dominant substrates 
for energy production in the unstressed heart, while glucose may become the favorable substrate 
in high-energy demand conditions (Depre, Vanoverschelde, & Taegtmeyer, 1999; Rosano, Fini, 
Caminiti, & Barbaro, 2008; Stanley, et al., 2005; Witteles & Fowler, 2008).  
 
While glucose metabolism has a greater capacity to generate ATP, glycolysis accounts for just 
5% of the ATP produced in the normal oxygenated heart (Abozguia, Shivu, Ahmed, Phan, & 
Frenneaux, 2009). In vitro and in vivo studies have demonstrated that glucose metabolism is 
inhibited by FAO and is dependent on the dietary state and physical activity of the body (Randle, 
Garland, Hales, & Newsholme, 1963; Randle, Newsholme, & Garland, 1964). This reciprocal 
relationship between FAs and glucose for oxidative metabolism was originally described by 
Randle et al. in 1963 (Randle, et al., 1963).  
The common end product, acetyl coenzyme A (acetyl-CoA), produced from FAO or from the 
glycolytic pathway, is transferred into the citric acid cycle (also known as the tricarboxylic acid 
[TCA] cycle or the Krebs cycle) (Kantor, Lopaschuk, & Opie, 2001). Acetyl-CoA in the Krebs 
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cycle generates one molecule of ATP via substrate phosphorylation and the formation of 
reducing equivalents – three molecules of nicotinamide adenine dinucleotide (NADH) and one 
molecule of FADH2 (Berg, Tymoczko, & Stryer, 2002). 
The metabolic flexibility of the heart is demonstrated by its ability to utilize energy substrates 
based on their availability and complex regulatory mechanisms (Kolwicz, Purohit, & Tian, 
2013). 
 
2.2  Shift of metabolic pathways in the progression of heart failure   
Altered energetics plays a key role in the pathophysiology of the failing heart, which switches 
from FA utilization to oxygen-sparing carbohydrate metabolism for energy production (Bedi, et 
al., 2016) (Figure 1). Chronic HF (CHF) is associated with abnormalities in skeletal muscle 
metabolism that affect exercise capacity and contributes to insulin resistance (IR) (Jordan, et al., 
2016). The metabolic alterations in cardiomyocytes depends on the stages of HF (early, mid or 
advanced) (Chandler, et al., 2004). Most studies show that FAO is unchanged or only slightly 
elevated in the early stages of HF(Chandler, et al., 2004; Stanley, et al., 2005). However, in 
advanced- or end-stage decompensated HF, there is a down-regulation in FAO enzyme 
expression, and FA utilization is decreased (Chandler, et al., 2004; Stanley, et al., 2005). Glucose 
utilization is typically increased in the early stages of HF (in the hypertrophied heart) and is 
mainly characterized by an increase in glucose uptake and glycolysis as a result of reduced 
oxidative metabolism (Allard, Schonekess, Henning, English, & Lopaschuk, 1994; Nascimben, 
et al., 2004). This increase in glucose metabolism could be due to alterations in the regulation of 
carbohydrate utilization pathways secondary to FAO suppression and/or upregulation of the 
anaplerotic pathway (Pound, et al., 2009; Sorokina, et al., 2007). In contrast, in advanced HF or 
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HF with type 2 diabetes, IR develops in the myocardium, resulting in decreased glucose 
metabolism (Kalsi, et al., 1999; Razeghi, et al., 2001; Taylor, et al., 2001). This shift from FAO 
to glucose metabolism is considered to be part of the ‘foetal reprogramming’ hallmark of cardiac 
hypertrophy and HF (Razeghi, et al., 2001). Gene expression profiling demonstrated early and 
sustained down-regulation of metabolic gene classes in HF (Rowell, Koitabashi, Kass, & Barth, 
2014). A number of studies have demonstrated that the failing heart exhibits decreased 
expression and activity of enzymes involved in mitochondrial FAO (Iemitsu, et al., 2002; Osorio, 
et al., 2002). The reduced glucose oxidation seen in advanced HF is attributed, at least in part, to 
mitochondrial dysfunction. Functional blockade of the pyruvate dehydrogenase (PDH) complex, 
the rate- limiting step in glucose oxidation, is also thought to play a major role in this process 
(Doehner, Frenneaux, & Anker, 2014).  
 
In addition to myocardial metabolism of glucose and fatty acids, the heart is also capable of 
oxidising a range of other substrates including ketone bodies, lactate and amino acids (Kolwicz, 
Airhart, & Tian, 2016). Ketone bodies compete with other substrates in the heart, especially FA, 
to be used as fuel. This is particularly significant in the hypertrophied and failing heart, wherein 
there is down-regulation of FAO gene expression (Tian & Barger, 2006) and increased blood 
ketone bodies (Lommi, et al., 1996). The increase in ketone bodies is proportionate to the level 
of cardiac dysfunction and neurohumoral activation (Lommi, et al., 1996). IR and cardiac 
cachexia are common features of advanced HF, which also increases the likelihood of ketone 
production and cardiac ketone utilisation (Schugar, et al., 2014). 
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The shift of energy metabolism to ketone body metabolism has been shown to be an efficient 
alternative avenue for oxidative ATP production (Aubert, et al., 2016). Ketone bodies, especially 
the principal ketone body D-β-hydroxybutyrate, have been proposed to act as a “superfuel”, 
producing more energy than FA or glucose (Aubert, et al., 2016; Cahill & Veech, 2003; Sato, et 
al., 1995). This shift to ketone body metabolism is supported by a further case-control study, that 
evaluated the metabolic signature in the human non-diabetic failing heart (Bedi, et al., 2016). 
This study showed that the metabolic and genetic profile characteristic of ketone oxidation was 
present in failing hearts only, suggesting that ketone utilization is a late event in HF. It has been 
suggested that the failing heart relies on ketone metabolism when other substrate metabolism 
pathways begin to shut down (Bedi, et al., 2016; Taegtmeyer, et al., 2016). These observations 
are supported by studies in advanced HF patients, which demonstrated that the use of circulating 
ketones was reduced by 50% in skeletal muscle, but was preserved in cardiac tissue (Janardhan, 
Chen, & Crawford, 2011). In contrast, a more recent animal study reported that increased levels 
of ketone bodies impairs α-ketoglutarate dehydrogenase activity and blocks the Krebs cycle, 
subsequently resulting in contractile dysfunction (Karlstaedt, et al., 2016). In cardiomyocytes, 
ketone bodies cause concurrent inhibition of glucose and FAO, thereby impairing myocardial 
energy supply (Taegtmeyer, 1994). Furthermore, the O2 consumed for ATP production during 
ketone metabolism is more efficient than FA, but less than that of glucose. However, more 
energy is derived from β-hydroxybutyrate versus glucose due to β-hydroxybutyrate being more 
reduced (Mudaliar, Alloju, & Henry, 2016). Interestingly, when β-hydroxybutyrate is infused in 
healthy volunteers to reach very high physiological levels, it is oxidized at the expense of 
glucose. Moreover, myocardial blood flow and heart rate also increase with the infusion of β-
hydroxybutyrate, (Gormsen, et al., 2017), a phenomenon previously also observed for the 
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kidney, brain and forearm (Fioretto, et al., 1987; Hasselbalch, et al., 1996; Walker, Fulcher, 
Marsiaj, Orskov, & Alberti, 1991).  
 
While these studies point to an important role of ketone bodies in cardiac metabolism and HF, it 
remains unclear whether ketone body metabolism is adaptive or maladaptive in heart failure. 
Targeted deletion of succinyl CoA-3-oxoacid CoA transferase (an enzyme essential for terminal 
oxidation of ketone bodies) in cardiomyocytes of mouse models of HF suggests that inability to 
oxidize ketones may predispose the heart to metabolic reprograming contributing to pathological 
remodeling following pressure overload (Schugar, et al., 2014). It has been suggested that 
myocardial ketone oxidation is a metabolic adaptation in the failing heart (Bedi, et al., 2016). 
Preference of ketone bodies over FA and glucose for oxidation to provide energy may not only 
improve cardiac function but also enhance cardiac efficiency (Ferrannini, Mark, & Mayoux, 
2016). Although it would appear that ketone bodies have a positive effect on cardiac function, 
further studies are needed to clarify the long-term effects of ketone metabolism in patients with 
HF.  
Perturbations in amino acid availablity and metabolism have also been observed in HF (Wende, 
et al., 2017). Accumulation of branched chain aminoacids (BCAA; including isoleucine, valine 
and the ketogenic aminoacid leucine) and their corresponding branched chain -keto acid 
(BCKA) derivatives due to defective catabolism has emerged as one of the hallmark signatures 
of the metabolic changes in failing heart (Sun, et al., 2016; W. Wang, et al., 2016; Wende, et al., 
2017). Elevated levels of BCKA may have a detrimental effect on cardiomyocytes due to 
cytotoxicity resulting from mitochondrial dysfunction and oxidative stress (Sun, et al., 2016). 
The accumulation of BCKAs has been attributed to transcriptional repression of subunits of the 
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BCKA dehydrogenase, a key enzyme involved in subsequent catabolism of BCKAs. These 
findings are further supported by the observation that pharmacolgical activation of BCKA 
dehyrdogenase prevents BCKA accumulation and improves cardiac function (Sun, et al., 2016). 
In addition to being potential sources of energy, BCAAs are also essentail for de novo protein 
synthesis and function as signaling molecules in various metabolic and growth pathways. For 
example, by activating mTOR, BCAAs (especailly lysine) may regulate diverse cellular 
processes like protein synthesis, autophagy and insulin signalling therby affecting glucose and 
FA metabolism, and muscle anabolism (Sun, et al., 2016; Wende, et al., 2017).  
 
2.3 Purinergic signaling in HF 
Purinergic signaling (ATP acting as extracellular signaling molecule) is mediated by purine 
receptors that are expressed in all cells of the heart and blood vessels including erythrocytes, 
leukocytes, and platelets (Burnstock, 2017; Burnstock & Knight, 2004; Burnstock & Pelleg, 
2015). There are four subtypes of P1 G protein-coupled receptors (GPCR) (A1, A2A, A2B, and 
A3), seven P2X (1–7) subtypes of ion channel receptors and eight subtypes P2Y GPCRs 
(P2Y1/2/4/6/11/12/13/14) (Burnstock, 2007b; Ralevic & Burnstock, 1998). They mediate actions on 
the heart which are described in original publications (Burnstock & Ralevic, 2014; Givertz, 
2009). The heart is controlled by the sympathetic, parasympathetic, and sensory nervous 
systems, which utilize ATP as a co-transmitter. Cardiac expression of purine receptors is 
increased in CHF patients (Hou, et al., 1999), with a resultant accumulation of adenosine in 
plasma (Funaya, et al., 1997). Furthermore, adenosine therapy has demonstrated cardioprotective 
effects in CHF patients, which are mediated through A1 and A3 receptors (Dougherty, Barucha, 
Schofield, Jacobson, & Liang, 1998; Liang & Jacobson, 1998).  
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Accumulating evidence supports the role of purinergic signaling in cardiac pathophysiology. An 
up-regulation of P2X1 and P2Y2 receptor mRNA was reported in the heart of a rat model of 
congestive HF (Hou, et al., 1999). Increased expression of P2X1 receptors has similarly been 
reported in the atria of patiens suffering from dilated cardiomyopathy (Berry, Barden, Balcar, 
Keogh, & dos Remedios, 1999). Early in-vivo studies have shown that regulated over-expression 
of A1 receptors leads to adverse ventricular remodeling. (Funakoshi, et al., 2006). This finding is 
in contrast to more recent data, indicating that adenosine accumulation may be cardioprotective 
in heart failure. Adenosine A1 receptor activation attenuated cardiac hypertrophy in rat neonatal 
cardiac myocytes (Chuo, et al., 2016). Partial adenosine A1 agonism has demonstrated promise 
as a treatment for heart failure, with the potential to enhance cardiac metabolism, calcium 
homeostasis, cardiac structure and function, and patient outcomes, when combined with standard 
therapies (Greene, et al., 2016). 
 
An association of purinergic signalling with cardiac energy metabolism has also been 
demonstrated, with animal studies showing that adenosine (an A1 receptor agonist) altered 
glucose metabolism and tended to decrease acidosis and calcium overload, exerting a 
cardioprotective effect. (Finegan, Lopaschuk, Coulson, & Clanachan, 1993; Fraser, Lopaschuk, 
& Clanachan, 1999; Puhl, et al., 2016). Adenosine inhibits adenyl cyclase and reduces 
intracellular levels of cyclic adenosine monophosphate (cAMP) (Akbar, Okajima, Tomura, 
Shimegi, & Kondo, 1994; Fredholm, AP, Jacobson, Klotz, & Linden, 2001; D. Wang & 
Belardinelli, 1994), subsequently leading to reduced sympathetic nervous system activation and 
increased release of atrial natriuretic peptide (ANP) (Schutte, Burgdorf, Richardt, & Kurz, 2006; 
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Yuan, Cao, Han, Kim, & Kim, 2005). Under hypoxic conditions, adenosine activates protein 
kinase C and improves mitochondrial function, by modulating mitochondrial sensitive potassium 
(mKATP) channels (Xiang, et al., 2010). 
 
HF is characterized by volume overload, a condition that is particularly relevant for the effect of 
adenosine on the renal systems. Renal dysfunction is a major co-morbidity of HF, with about 
half of patients with CHF and two-thirds of patients with acute HF (AHF) presenting with 
associated cardiorenal syndrome (CRS) (Ronco, Haapio, House, Anavekar, & Bellomo, 2008). 
Adenosine has multiple, complex effects on the kidney, including vasoconstriction of afferent 
renal arterioles, sodium reabsorption in the proximal tubules and enhanced tubuloglomerular 
feedback (TGF) in the macula densa (Vallon, Muhlbauer, & Osswald, 2006). CHF is 
characterized by an increased accumulation of endogenous adenosine in plasma (Funaya, et al., 
1997; Vallon, Miracle, & Thomson, 2008). In the kidney, adenosine can induce both 
vasoconstriction via the A1 receptor (in the outer cortex) and vasodilation via the A2 receptor (in 
the deep cortex and medulla) (Vallon, et al., 2008). The effect of adenosine on TGF plays a key 
role in the progression of the disease (Burnstock & Pelleg, 2015; Givertz, 2009). Increased renal 
adenosine levels mediate A1 receptor activation and causes fluid retention by stimulating NaCl 
and fluid reabsorption in the proximal tubule (Vallon, et al., 2008). The net effect of these is 
fluid overload and decreased glomerular filtration rate (GFR). 
  
2.4 Cardiac implications of co-morbidities 
Metabolic syndrome: Metabolic syndrome (MetS) refers to a cluster of risk factors that can lead 
to heart disease, including obesity, dyslipidemia, elevated blood pressure and glucose 
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intolerance/IR.(American Heart Association, 2016; Hanefeld, Pistrosch, Bornstein, & Birkenfeld, 
2016). Alterations in substrate availability/utilization and impairment in transcriptional 
regulation of oxidation pathways is often noted in MetS (Ilkun & Boudina, 2013). IR-mediated 
impairment of glucose transport leads to enhanced long-chain FA uptake through relocation of 
the FA transporter CD36 to the sarcolemma (Ouwens, et al., 2007) and increased mitochondrial 
carnitine palmitoyltransferase-1 (CPT-1) activity (Menard, et al., 2010). 
 
There is mounting evidence to support the role for increased FA levels (as seen in MetS and 
diabetes mellitus [DM]) in mitochondrial oxidative dysfunction. The mechanism promotes 
cardiac lipotoxicity, myocardial damage, myocyte apoptosis, reduced contractility, and 
subsequent myocardial dysfunction (Lehrke & Marx, 2017; Schulze, Drosatos, & Goldberg, 
2016; Seferovic, et al., 2018). Early studies in patients with obesity noted the accumulation of 
lipids around the epicardium, (Carpenter, 1962) a phenotype that was associated with cardiac 
dysfunction (Alpert, 2001; Carpenter, 1962). The link between lipid accumulation and heart 
failure is summarised in a recent review in the area(Schulze, et al., 2016). An improvement in 
cardiac metabolism and function in response to reduction in toxic lipids has been reported (I. J. 
Goldberg, Trent, & Schulze, 2012). Key evidence for this effect is summarised in the following 
sections. 
 
Diabetes mellitus: Patients with type 2 DM (T2DM) have a two to three times increased risk of 
CV mortality compared to those without T2DM (Emerging Risk Factors, et al., 2015). CV 
mortality accounts for approximately 80% of deaths in patients with T2DM (M. Abdul-Ghani, 
Del Prato, Chilton, & DeFronzo, 2016). Data suggest that HF may lead to IR and DM (Amato, et 
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al., 1997; Swan, et al., 1997). DM and IR impairs the ability of the heart to adjust to changing 
energy demands by reducing the ability of the heart to use glucose and increasing the delivery of 
FA to the heart, thereby shifting cardiac metabolism towards a greater reliance on FA for 
energy(Bayeva, Sawicki, & Ardehali, 2013). In support of this observation, IR was found to be 
associated with myocardial triglyceride accumulation, cardiac remodeling and impaired diastolic 
function in overweight and obese women (Utz, et al., 2011). Greater dependence of the diabetic 
heart on FAO results in increased mitochondrial oxygen consumption in addition to increased 
cellular stress from elevated reactive oxygen species (ROS) production, and mitochondrial 
dysfunction (Dietl & Maack, 2017; Feuvray, 2010). These changes in myocardial metabolism 
may contribute to structural and functional alterations in the heart that can lead to progression of 
HF (Carley & Severson, 2005; Stanley, et al., 2005).  
 
3. CURRENT THERAPIES AND THEIR EFFECTS ON CARDIAC METABOLISM  
Current treatments for HF, aim at blocking neurohormonal signaling. However, more recently 
these therapies have been proposed to affect cardiac metabolism and associated energetics 
(Neubauer, 2007) (Figure 2A and 2B). The cardiac metabolic effects of some of the major HF 
therapies are described in the following sections.  
 
β-blockers: β-adrenergic blockers are one of the main therapies that improve patient survival in 
HF. In these patients, long-term upregulation of catecholamines results in IR by antagonizing 
insulin, increasing lipolysis and raising free FA (FFA) levels (Nonogaki, 2000; Witteles & 
Fowler, 2008). Adrenergic blockade with carvedilol and metoprolol helps to improve myocardial 
function and survival in patients with HF through several mehanisms, including an energy-
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sparing effect, possibly by favouring altered myocardial substrate utilization from FFA to 
glucose oxidation (Bayeva, et al., 2013; Eichhorn, et al., 1994; Wallhaus, et al., 2001). However, 
it is important to note the differences in the phramacological effects of various β-blockers on 
metabolism (Bayeva, et al., 2013).  
 
Renin-angiotensin-aldosterone system (RAAS) inhibitors: The failing heart is associated with 
increased renin–angiotensin–aldosterone system activity (Mizuno, et al., 2001; Nakamura, et al., 
2004; Yoshimura, et al., 2002). Prolonged activation of the RAAS system contributes to altered 
insulin/insulin-like growth factor 1 (IGF-1) signaling pathways and ROS formation, resulting in 
endothelial dysfunction and IR (Cooper, et al., 2007). Unlike β-blockers, ACEIs have been 
shown to increase FA uptake and improve myocardial energetics in HF. Studies in animal 
models with obesity and IR have shown that ACEIs can improve insulin responsiveness in the 
heart (Kadkhodayan, Coggan, & Peterson, 2013; Tabbi-Anneni, Buchanan, Cooksey, & Abel, 
2008). Chronic ACE inhibition causes inactivation of bradykinin, which in turn has favorable 
effects on glucose uptake, glucose oxidation and glycolysis (Mori, Zhang, Oudit, & Lopaschuk, 
2013). Furthermore, trials comparing the effects of ACEIs or ARBs with anti-hypertensive 
medicines have also demonstrated that RAAS blockade significantly improves insulin sensitivity 
(Grassi, et al., 2003; Jin & Pan, 2007; Olsen, et al., 2005). In-vitro studies with human 
adipocytes suggests that some ARBs can activate PPAR- target genes and induce adipogenesis 
(Janke, et al., 2006). As seen with ACEIs and ARBs, mineralocorticoid receptor antagonists can 
also increase glucose metabolism and restore insulin sensitivity (Pfeffer, et al., 2003; Yusuf, et 
al., 2000) (Vecchiola, Lagos, Carvajal, Baudrand, & Fardella, 2016). 
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Angiotensin receptor blocker-neprilysin inhibitors (ARNi): Sacubitril/valsartan (ARNi), acts by 
simultaneously blocking the RAAS and neprilysin (Ruilope, et al., 2010). Neprilysin degrades 
the peptides that have the potential to modulate lipid and glucose metabolism, such as natriuretic 
peptides (NPs), bradykinin, endothelin-1, and glucagon- like peptide 1 (GLP-1) (Standeven, et 
al., 2011). Neprilysin inhibition with sacubitril/valsartan increases the activity of NPs, 
bradykinin, GLP-1 and skeletal muscle cGMP, but decreases dipeptidyl peptidase 4 (DPP4) 
activity. Treatment with sacubitril/valsartan in normoglycemic patients with obesity and 
hypertension resulted in increased insulin sensitivity (Jordan, et al., 2017). A more recent study 
that compared the effects of sacubitril/valsartan with a comparator, amlodipine, demonstrated 
that sacubitril/valsartan did not elicit any clinically relevant changes in exercise-induced lipolysis 
or substrate oxidation in these patients with obesity and hypertension, suggesting that that the 
cardiovascular benefits of sacubitril/valsartan are not attributable to changes in lipid metabolism 
during exercise (Engeli, et al., 2018).  
 
Natriuretic peptides (NPs): NPs can favorably affect human lipid metabolism by increasing 
lipolysis and insulin sensitization, while leptin release is suppressed (Birkenfeld, et al., 2012; 
Birkenfeld, et al., 2005; Birkenfeld, et al., 2008; Kerkela, Ulvila, & Magga, 2015; Moro, 2016; 
Schlueter, et al., 2014). NPs have been shown to improve energy production by enhancing 
mitochondrial biogenesis and oxidative capacity in skeletal muscle and adipose tissue 
(Bordicchia, et al., 2012; Engeli, et al., 2012; Kerkela, et al., 2015). In skeletal muscle, NPs can 
increase mitochondrial oxidative metabolism and lipid oxidation, thereby augmenting energy 
metabolism (Engeli, et al., 2012). ANP and BNP are potent mediators of lipolysis as compared 
with CNP that has a minor lipolytic effect (Sengenes, Berlan, De Glisezinski, Lafontan, & 
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Galitzky, 2000). In mice, transgenic BNP over-expression attenuates high-fat feeding- induced 
adiposity and IR (Miyashita, et al., 2009). Obesity and T2DM are associated with NP deficiency, 
thus suggesting a possible role of NPs in the pathophysiology of these diseases (Schlueter, et al., 
2014). Finally, polymorphisms in the genes encoding atrial natriuretic peptide (ANP) and BNP 
contribute to the variability in the risk for T2DM (Jujic, et al., 2014; Meirhaeghe, et al., 2007). 
Previous studies have shown that ANP promotes adipose tissue lipolysis and hepatic ketogenesis 
(Birkenfeld, et al., 2008). The natriuretic system in adipose tissue is not desensitized in CHF. 
The lipolytic response to ANP is therefore preserved, ensuring that cardiac metabolism is 
maintained (Birkenfeld, Adams, Schroeder, Engeli, & Jordan, 2011). 
NPs are degraded either through enzymatic degradation by neprilysin or via cellular uptake 
through the NP-C receptor. Evidence from various non-clinical and clinical studies has 
established the role of neprilysin inhibition in augmentation of the NP system (Doenst, et al., 
2010; Jordan, et al., 2016; Kobalava, et al., 2016; Kuhn, 2016).  
Recombinant ANP (carperitide) and BNP (nesiritide) were approved in 1995 and 2001 
respectively for treatment of congestive HF. However, nesiritide was shown to be ineffective in 
reducing HF rehospitalization or death from any cause in the Acute Study of Clinical 
Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF) (O'Connor, et 
al., 2011). Cenderitide, a chimeric peptide that activates natriuretic peptide receptor (NPR) A and 
NPRB, is being tested for preservation of left ventricular (LV) function in post-MI patients 
(Kerkela, et al., 2015). 
 
Sodium glucose cotransporter (SGLT) inhibitors: SGLT inhibtiors belong to a class of drugs that 
inhibit glucose reabsorption in the kidney, thereby increasing urinary glucose excretion and 
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providing an important therapeutic strategy for the treatment of T2DM (M. A. Abdul-Ghani, 
Norton, & Defronzo, 2011). Among the two most well known SGLTs, 90% of glucose 
reabsorption is via SGLT-2 and the remaining 10% is via SGLT1(Hediger & Rhoads, 1994). 
Dapagliflozin (List, Woo, Morales, Tang, & Fiedorek, 2009), empagliflozin (Grempler, et al., 
2012) and canagliflozin (Neal, et al., 2017) are recently developed selective SGLT-2 inhibitors 
that have been investigated for the treatment of T2DM. 
 
An earlier study that evaluated the efficacy and safety of dapagliflozin in patients with T2DM 
and pre-existing cardiovascular disease (CVD), showed that dapagliflozin significantly reduced 
haemoglobin A1c (HbA1c) (−0.38% [−4.2 mmol/mol]), body weight and systolic blood pressure 
without adversely affecting CV safety relative to placebo (Cefalu, et al., 2015). Another recent 
study, the Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus 
Patients study (EMPA-REG OUTCOME), has shown that treatment with SGLT-2 inhibitor 
empagliflozin has beneficial cardio-metabolic effects in patients with T2DM and established 
CVD. A 14% reduction in primary major adverse cardiac events was observed in addition to a 
35% reduction in HF hospitalizations (Zinman, et al., 2015). 
 
The results of the EMPA-REG trial have been validated from the CANVAS program (Neal, et 
al., 2017). CANVAS indicated that canagliflozin reduces CV events by 14%, and the rate of 
renal decline by 40%, although at an increased risk of lower-limb amputation and bone fractures. 
Clinical practice guidelines have already begun to reflect the efficacy of SGLT-2 inhibitors in 
this group of patients and will impact on clinical decision making in cardiologists (Ponikowski, 
et al., 2016; Tanaka & Node, 2017). 
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Finally, SGLT-2 inhibitors increase ketone body availability by increasing FAO in the liver via 
β-oxidation. Indeed, a recent untargeted metabolomic study showed an increase in the levels of 
ketone bodies as well as branched chain amino acids in patients with T2DM and CV disease 
treated with empagliflozin (Kappel, et al., 2017). Ketone bodies (acetoacetate and β-
hydroxybutyrate) are then exported from the liver into blood stream and are utilized by the heart 
in preference to FA, resulting in more efficient oxidation and increase ATP hydrolysis to 
produce energy (Ferrannini, et al., 2016). Moreover, treatment with SGLT-2 inhibitors also 
increases haematocrit and erythropoietin, possibly improving oxygen delivery to tissues and 
organs (Ferrannini, et al., 2017; Ferrannini, et al., 2016; Lambers Heerspink, de Zeeuw, Wie, 
Leslie, & List, 2013).  
 
Glucagon-like peptide-1 (GLP-1) receptor agonists:  
GLP-1 receptors are expressed in the endothelium and cardiac and vascular myocytes. GLP-1 
administration in isolated mouse heart showed cardioprotective effects by increasing glucose 
uptake, cAMP and cGMP release, left ventricular developed pressure, and coronary flow (Ban, et 
al., 2008). Lixisenatide, a GLP-1 receptor agonist was shown to be safe in patients with diabetes 
and acute coronary syndrome (ACS) in ELIXA trial (Pfeffer, et al., 2015). The long-acting 
liraglutide and very-long-acting semaglutide demonstrated superiority over placebo in reducing 
the occurence of CV events in high-risk patients with diabetes in LEADER and SUSTAIN-6 
trials, respectively (Marso, Bain, et al., 2016; Marso, Daniels, et al., 2016) . Furthermore, a non-
significant reduction in HF hospitalizations was observed in liraglutide treatment (Margulies, et 
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al., 2016). However, liraglutide treatment did not improve clinical outcomes in HFrEF patients 
with or without diabetes (Jorsal, et al., 2017).  
 
4. RELEVANCE FOR CLINICAL PRACTICE – TARGETING DYSREGULATED 
METABOLIC PATHWAYS IN HEART FAILURE  
4.1 Optimizing myocardial substrate utilization – glycolysis and FA metabolism 
Several therapeutic strategies to optimize myocardial substrate utilization in HF have been 
investigated suggesting that metabolic therapy may be an important therapeutic option (Rosano, 
Vitale, & Spoletini, 2015). Table 1 summarizes the studies of cardiac metabolism modulators 
and their clinical benefits. 
 
Fatty acid oxidation inhibitors: Reversal of the metabolic ‘foetal reprogramming’ that is 
characteristic of HF would aim to metabolise substrates as quickly as possible using the available 
oxygen. However, it is not desirable to depend on FAO under HF conditions in which oxygen 
demands are increased and supply limited. There is a risk of lipotoxicity and the oxidative 
capacity of the cardiomyocytes is also limited (due to reduced mitochondrial mass). An 
alternative approach would be to block FAO to stimulate the heart to switch to glucose oxidation 
(Heggermont, Papageorgiou, Heymans, & van Bilsen, 2016). In support of this approach, 
postinfarction HF was associated with upregulation of the glucose transporter, GLUT-1 in rats, 
while GLUT-1 overexpression prevented the developement of HF in a mouse model (Liao, et al., 
2002; Rosenblatt-Velin, Montessuit, Papageorgiou, Terrand, & Lerch, 2001). Etomoxir and 
perhexiline are inhibitors of CPT-1, which also block FAO. They decrease the activity of this 
rate-limiting enzyme in FAO pathway, while favoring glucose oxidation (via the Randle Cycle) 
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(Lam & Lopaschuk, 2007). Studies with etomoxir have shown that it can improve cardiac 
function by enhancing sarcoplasmic Ca2+ handling and increasing sarco/endoplasmic reticulum 
Ca2+-ATPase (SERCA)2A (Rupp & Vetter, 2000; Zarain-Herzberg, Rupp, Elimban, & Dhalla, 
1996). However, its association with serious side effects (including hepatotoxicity caused by 
increased liver transaminase levels) means that etomoxir is not considered a suitable therapy for 
use in HF patients (Holubarsch, et al., 2007).  
 
Perhexiline is an anti-anginal drug that inhibits the cardiac, but not hepatic isoform of CPT-1 and 
is associated with improved exercise capacity and left ventricular ejection fraction (LVEF) in 
patients with HF (Lee, et al., 2005). Trimetazidine (TMZ) is a second anti-anginal agent, which 
has been approved world-wide (in many European countries) (Beadle & Frenneaux, 2010). It has 
anti-ischemic actions without causing central hemodynamic effects. TMZ belongs to a group of 
inhibitors known as ‘partial fatty-acid oxidation’ (PFox) inhibitors (Fragasso, et al., 2006). It 
exerts its effects by causing a shift in cardiac energy metabolism to glucose metabolism. The 
response results in a greater production of high-energy phosphates (increase in cardiac 
phosphocreatinine: ATP ratio by 33%) (Fragasso, et al., 2006) and causes an anti-ischemic 
effect. In addition, TMZ is known to cause an improvement in endothelial function, a reduction 
in calcium overload and free radical-induced injury (improved reperfusion mechanical function), 
(Fragasso, et al., 2003; Gambert, et al., 2006) and an inhibition of cell apoptosis and cardiac 
fibrosis (L. Zhang, et al., 2016) There is a growing evidence to support the efficacy of TMZ in 
improving LV function, cardiac volume, contractility, inflammation, endothelial function and 
fasting glucose levels (Rosano, et al., 2015).  
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Ranolazine is an inhibitor that is similar in structure and function to TMZ (also a PFox inhibitor). 
It acts by blocking FAO to enhance glucose oxidation, thus indirectly increasing PDH complex 
activity, and resulting in increased ATP production (McCormack, Barr, Wolff, & Lopaschuk, 
1996). It is currently approved as an anti-anginal agent in Europe and the USA. It has been 
shown to inhibit the late sodium current and normalize Ca2+ elimination in cardiac myocytes in 
end-stage HF, thus improving myocardial diastolic function and reducing diastolic wall tension 
(Sossalla, et al., 2008). Furthermore, ranolazine has been shown to significantly increase LVEF 
in patients with systolic and diastolic HF (Horvath & Bers, 2014). 
 
The RAnoLazine for the Treatment of Diastolic Heart Failure study (RALI-DHF) was a 
randomized, prospective, placebo-controlled study in diastolic HF patients (ranolazine=12; 
placebo=8) with ejection fraction (EF) ≥45%. The study concluded that ranolazine improves 
haemodynamic measurements (reduction in LV end-diastolic pressure and pulmonary capillary 
wedge pressure) in patients with HF. However, no significant effects on relaxation parameters or 
BNP concentrations were observed (Maier, et al., 2013).  
 
Peroxisome proliferator-activated receptor agonists (PPARs): PPARs play a role in the 
modulation of glucose homeostasis, IR and blood pressure (Desvergne & Wahli, 1999; Willson, 
Lambert, & Kliewer, 2001). PPARα agonists, such as fibrates, mediate the hypolipidaemic action 
of the thiazolidinediones (TZDs), while the PPARγ agonists act as receptors for these glitazones 
(Barbier, et al., 2002). PPARs decrease the circulating FFA supply to the heart, resulting in 
reduced cardiac FAO rates (Lopaschuk, et al., 2010). A systematic review concluded that fibrates 
lower the risk of major CV and coronary events compared with placebo, but do not affect the risk 
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of CV or all-cause mortality or prevent the development of HF (Jun, et al., 2010). PPARγ 
agonists, TZDs (rosiglitazone and pioglitazone), are used to treat patients with T2DM. A 
systematic study analysed the CV outcomes in patients with T2DM using TZDs, concluded that 
rosiglitazone is associated with a higher risk of congestive HF, myocardial infarction (MI), and 
death than pioglitazone (Loke, Kwok, & Singh, 2011). TZDs affect lipid metabolism, and cause 
a significant increase in triglyceride and low density lipoprotein cholesterol levels. This effect 
was greater with rosiglitazone than with pioglitazone (R. B. Goldberg, et al., 2005). Furthermore, 
rosiglitazone, exhibited a more powerful renal PPARγ agonistic effect, leading to more fluid 
retention, a worsening of HF, and an increased in HF-associated hospitalizations (Loke, et al., 
2011; H. Zhang, et al., 2005).  
 
4.2 Ketone bodies  
Ketone bodies are an alternative and glucose-sparing fuel source, which are frequently oxidized 
in the heart and skeletal muscle. Studies in both animal models (Aubert, et al., 2016) and humans 
(Bedi, et al., 2016), have demonstrated that ketone utilization is increased in HF. These are in 
contrast to the more recent observation that increased levels of ketone bodies may lead to 
contractile dysfunction (Taegtmeyer, 2017). Ferrannini et al pointed to the hypothesis that β-
hydroxybutyrate is freely taken up by the heart during persistent, but mild hyperketonemia (such 
as that seen during treatment with SGLT-2 inhibitors) and utlized in preferance to FAs. 
(Ferrannini, et al., 2016). Such a mechanism may provide some explanation for the 
cardioprotection observed in the EMPA-REG study (Zinman, et al., 2015). While these studies 
have already been discussed in detail in the section on ketone metabolism (section 2.2), they 
suggest an ongoing debate surrounding the role of ketone bodies in HF. Recent studies suggest 
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that ketone oxidation may be a key metabolic adaptation in human HF , implying that reducing 
ketone utilization may be a valuable therapeutic approach (Kappel, et al., 2017; Wende, et al., 
2017). However, further studies are required to fully uncover the effect of chronic ketone 
utilization on cardiac metabolism and function.  
 
4.3 Purinergic signaling  
Several studies have assessed the effects of modulators of purinergic signaling on cardiac 
metabolism. Dipyridamole (DIP) is an adenosine uptake blocker that causes increased adenosine 
levels (Stea, et al., 2016). Small observational studies in patients with HF have shown that DIP 
improves LV function, symptoms (New York Heart Association [NYHA] class) and exercise 
capacity (Akhtar, Ordovas, Martin, Higgins, & Michaels, 2007; Sanada, et al., 2007). Rolofylline 
is an adenosine A1 receptor antagonist that increased diuresis in patients with AHF (Givertz, et 
al., 2007) and significantly increased GFR and renal plasma flow in CHF (Givertz, et al., 2007). 
This suggests that rolofylline may have potential for the clinical treatment of renal dysfunction in 
HF. 
In a dose-ranging pilot study in 301 patients with AHF, rolofylline demonstrated short and 
medium-term clinical benefits in association with renal protection (Cotter, et al., 2008). 
However, the results from the pivotal study, PROTECT (A Placebo-controlled Randomized 
Study of the Selective A1 Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized 
With Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on 
Congestion and Renal Function) did not demonstrate a renal-protective effect in 2033 patients 
admitted with acute decompensated heart failure (ADHF) and renal dysfunction, despite 
similarities in study design, inclusion criteria, and dose of rolofylline in the pilot study (Massie, 
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et al., 2010). The authors concluded that the inconsistency in study results could be due to the 
complexity and heterogeneity of AHF and suggested that new therapeutic approaches are 
needed. Similar to PROTECT, the REACH UP study did not demonstrate any CV benefit with 
rolofylline in patients with acute decompensated HF and worsening renal function (Gottlieb, et 
al., 2011). 
 
The Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial (Mahaffey, et al., 
1999) and AMISTAD II (Ross, et al., 2005) studied the effect of adenosine on infarct size in MI 
patients. While a significant reduction in infarct size was reported following adenosine treatment 
in AMISTAD (patients within 6 h of an onset of MI), this effect could not be replicated in 
AMISTAD II, in which infarct size was assessed in ST-segment elevation in MI patients 
undergoing reperfusion therapy. The authors noted that infarct size was reduced in patients 
receiving a higher concentration of adenosine (70-µg/kg/min infusion). suggesting that a larger 
study at the 70-µg/kg/min dose is warranted. 
 
AICA-riboside, otherwise known as acadesine, acts by increasing the adenosine bioavailability. 
By activating the 5’ adenosine monophosphate pathway, it increases the ATP production. 
However, development of acadesine was terminated after an analysis that suggested the drug had 
a low probability of reducing cardiovascular events in patients who underwent coronary artery 
bypass surgery (CABG) (NCT00872001). 
  
5. CONCLUSION 
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Shifting myocardial energetics from FAO to favor more energy-efficient metabolic pathways 
have the potential to improve cardiac function and prognosis in HF. Furthermore, the use of 
insulin-sensitizing agents may promote the ability of glucose to be utilized as a preferred 
metabolic substrate in HF. Given that current HF therapies and/concepts, including purinergic 
signaling are known to have effects on metabolic pathways, agents that leverage more efficient 
myocardial energetics should be further investigated.  
 
In the future, it is hoped that HF patients will not only be stratified according to their LVEF and 
any associated co-morbidities, but also according to their individual metabolic status allowing 
personalized metabolic treatment for each patient that is tailored to their specific metabolic 
needs.  
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TABLE 1: Clinical studies using metabolic modulators 
 
Metabolic 
modulator 
Metabolic mechanism 
affected by modulator  
Study type 
(pre-clinical studies, POC studies, pilot studies and 
clinical trials)* 
β-blockers 
Non-vasodilators 
 
 
 
 
 
 
 
Vasodilators 
Carvedilol 
Carvedilol/metoprolo
l 
Talinolol/atenolol 
 
Carvedilol/bisoprolol 
 
↓ insulin sensitivity 
↑ glucose levels  
Neutral/negative effect on 
lipid metabolism 
 
 
 
 
 
↓ FFA metabolism 
 
 
 
↑ glucose metabolism 
 
Prospective study; ARIC (n=12,550)(Gress, Nieto, Shahar, 
Wofford, & Brancati, 2000)  
Double-blind, prospective, parallel-group study; LIFE 
(n=8,300)(Dahlof, et al., 2002)  
Prospective, randomized, open-blinded study; INVEST 
(n=22,576)(Pepine, et al., 2003)  
Prospective, randomized, open-blinded study; ASCOT-BLA 
(n=19,257) (Gupta, et al., 2008) 
 
 
Pilot study (n=9)(Wallhaus, et al., 2001) 
Double-blind, randomized study (n=72)(Jacob, et al., 1996) 
Double-blind, randomized study; TALIP (n=198)(Sourgens, 
Schmidt, & Derendorf, 2003) 
Randomized study (n=26)(Podbregar & Voga, 2002) 
ACE inhibitors 
Captopril 
 
Ramipril 
 
↑ insulin sensitivity 
 
↑ insulin sensitivity 
 
In vivo study in ob/ob mice(Tabbi-Anneni, et al., 2008) 
Double-blind, randomized Heart Outcomes Prevention 
Evaluation study (n=9297)(Yusuf, et al., 2000) 
ARBs 
Candesartan 
 
 
↑ glucose metabolism 
 
 
Parallel, randomized, double-blind, controlled trials; 
CHARM-Overall program (n=7601)(Pfeffer, et al., 2003) 
SGLT-2 inhibitors  
Canagliflozin 
 
 
Empagliflozin 
 
 
Dapagliflozin 
 
 
 
↑ glucose  
metabolism/excretion 
 
↑ glucose  
metabolism/excretion 
 
↑ glucose  
metabolism/excretion 
 
Randomized, double-blind, placebo-controlled trials; 
CANVAS program (n=10,142)(Neal, et al., 2017) 
 
Randomized, double-blind, placebo-controlled trial (EMPA-
REG; n=7020)(Zinman, et al., 2015)  
 
Randomized, placebo-controlled, double-blind trial 
(n=75)(Lambers Heerspink, et al., 2013) 
GLP-1receptor 
agonists 
Lixisenatide 
 
 
Liraglutide 
 
Semaglutide 
 
 
Inhibit glucagon secretion 
↑ insulin secretion 
 
Inhibit glucagon secretion 
↑ insulin secretion 
 
Inhibit glucagon secretion 
↑ insulin secretion  
 
 
 
 
Randomized, double-blind, placebo-controlled trial 
(ELIXA; n=6068)(Pfeffer, et al., 2015) 
 
Randomized , double-blind, placebo-controlled trial 
(LEADER; n=9340)(Marso, Daniels, et al., 2016) 
 
Randomized , double-blind, placebo-controlled trial 
(SUSTAIN-6; n= 3297) (Marso, Bain, et al., 2016) 
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CPT-1 inhibitors 
Etomoxir 
 
 
 
Perhexiline 
 
 
↓ FFA metabolism 
 
 
 
↓ FFA metabolism 
 
 
In-vivo rat model(Zarain-Herzberg, et al., 1996) 
Randomized, double-blind study; ERGO 
(n=350)(Holubarsch, et al., 2007) 
 
In-vivo rat model (Rupp & Vetter, 2000) 
Randomized, double-blind, 
placebo-controlled, parallel-group study (n=50)(Beadle, et 
al., 2015) 
Randomized, double-blind study (n=56)(Lee, et al., 2005) 
Randomized, double-blind, placebo-controlled study 
(n=72)(Singh, et al., 2014) 
Other anti-anginal 
agents 
Trimetazidine 
 
 
 
 
 
 
 
Ranolazine 
 
 
 
 
↓ FFA metabolism 
 
 
 
 
 
 
 
↑ glucose metabolism 
 
 
Ex vivo rat model(Gambert, et al., 2006) 
In vivo rat model(L. Zhang, et al., 2016) 
Randomized open-label study (n=55)(Fragasso, et al., 2006)  
Randomized, double-blind, crossover study 
(n=16)(Fragasso, et al., 2003) 
Double-blind parallel group study (n=149)(Detry, et al., 
1994)  
 
Ex vivo rat model(McCormack, et al., 1996) 
Ex vivo explant model (n=14)(Sossalla, et al., 2008) 
Double-blind, placebo-controlled, randomized study, 
(MERLIN)-TIMI 36 (n=6560)(Morrow, et al., 2007) 
Randomized, double-blind, placebo-controlled POC study; 
RALI-DHF (n=20)(Maier, et al., 2013) 
PPAR agonists 
Fibrates 
Thiazolidinediones  
 
Pioglitazone 
 
↓ triglycerides  
↑ insulin sensitivity 
 
Systemic review & meta-analysis(Jun, et al., 2010)* 
Systemic review & meta-analysis(Loke, et al., 2011)* 
 
Randomized controlled trial (n=802)(R. B. Goldberg, et al., 
2005) 
Randomized, double-blind, double-dummy with active 
comparator, intervention; PIRAMID (n=78)(van der Meer, 
et al., 2009) 
ARNi 
Sacubitril/valsartan 
 
↑ insulin sensitivity 
↑ abdominal adipose 
lipolysis (NS) 
No change in whole body 
lipolysis and in exercise 
induced lipolysis  
 
Randomized, double-blind, double-dummy, active-
controlled, and parallel-group (n=98)(Engeli, et al., 2018; 
Jordan, et al., 2016) 
Natriuretic 
peptides 
↑ fatty acids  
 
↑ lipolysis  
 
↑ postprandial energy 
expenditure 
 
↑ adiponectin 
 
↑ adiponectin 
 
↓ ghrelin (induced by BNP) 
Human physiological study (n=14)(Birkenfeld, et al., 2005) 
 
Cross-over study (n=10)(Birkenfeld, et al., 2006) 
 
Randomized, double-blind, cross-over study 
(n=12)(Birkenfeld, et al., 2008) 
 
Human physiological study (n=12)(Birkenfeld, et al., 2012) 
 
Human physiological study (n=47)(Yamaji, et al., 2009) 
 
Randomized, placebo-controlled, crossover, single-blinded 
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*Systematic review and meta-analysis 
Abbreviations: ACEi, angiotensin converting enzyme inhibitors; AMISTAD, Acute Myocardial Infarction STudy of 
Adenosine; ARB, angiotensin II receptor blockers; ARIC, Atherosclerosis Risk In Communities; ARNI, angiotensin 
receptor blocker–neprilysin inhibitor; ASCOT-BPLA, Anglo-Scandinavian Cardiac Outcomes Trial – Blood Pressure 
Lowering Arm; BNP, B-type natriuretic peptide; CANVAS Program, The Canagliflozin Cardiovascular Assessment 
Study and CANVAS-Renal; CHARM, Candesartan in Heart Failure-Assessment of Reduction in Mortality and 
Morbidity; EMPA-REG, Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes trial; ERGO, 
etomoxir for the recovery of glucose oxidation; FFA, free fatty acid; INVEST, International Verapamil-Trandolapril 
Study; LIFE, Losartan Intervention for Endpoint Reduction; MERLIN-TIMI 36, Metabolic Efficiency With 
Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndromes; PIRAMID, Influence on 
tRiglyceride Accumulation in the Myocardium in Diabetes; POC, proof of concept; PPAR, Peroxisome proliferator-
activated receptor; PROTECT, Placebo-Controlled Randomized Study of the Selective A(1) Adenosine Receptor 
Antagonist Rolofylline for Patients Hospitalized With Acute Decompensated Heart Failure and Volume Overloa d to 
Assess Treatment Effect on Congestion and Renal Function; SGLTi, sodium glucose cotransporter inhibitors  
 
study (n=10)(Vila, et al., 2012) 
Ketone bodies ↑ β-hydroxybutyrate 
dehydrogenase-1 causing 
increased delivery and 
uptake of ketone bodies 
In vivo mouse model(Aubert, et al., 2016) 
Ex vivo explant model (n=35)(Bedi, et al., 2016) 
Purinergic 
signaling 
Dipyridamole 
 
 
 
Rolofylline 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adenosine 
 
 
↓ adenosine uptake and ↑ 
diuretic responsiveness 
 
 
Adenosine A1 receptor 
antagonist. ↑ diuretic 
responsiveness 
 
 
Pilot study (n=6)(Akhtar, et al., 2007) 
Prospective, open, randomized, controlled trial 
(n=28)(Sanada, et al., 2007) 
 
Randomized, double-blind, placebo-controlled, POC 
(n=146)(Givertz, et al., 2007) 
Randomized, double-blind, placebo-controlled, two-way 
crossover study (n=32)(Givertz, et al., 2007) 
Pilot: PROTECT−randomized, placebo-controlled, 
dose-finding study (n=301)(Cotter, et al., 2008) 
Double-blind, placebo-controlled study (n=2033)(Massie, et 
al., 2010) 
REACH UP study− randomized,  
double-blind, placebo-controlled (n=76)(Gottlieb, et al., 
2011) 
Prospective, open-label, placebo controlled, randomized 
study; AMISTAD (n=236)(Mahaffey, et al., 1999) 
Double-blind, placebo-controlled, randomized study; 
AMISTAD-II (n=2,118)(Ross, et al., 2005) 
L-carnitine ↑ glucose metabolism 
 
Ex vivo rat model (Broderick, Quinney, Barker, & 
Lopaschuk, 1993) 
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Figure legends 
Figure 1: Pathological changes in the healthy heart leading to insulin resistance (IR) and the 
development of heart failure. Mechanical dysfunction and other associated co-morbidities 
(obesity, diabetes, and metabolic syndrome) can lead to IR. Increased insulin levels lead to 
metabolic disturbances in adipose tissue, liver, and skeletal muscle. Metabolic perturbations in 
these systems can subsequently promote the progression to heart failure.  
 
Figure 2A: Overview of major targets of metabolic modulators. Several metabolic modulators 
exert their effects on cardiac metabolism indirectly through effects on other organs and cell types 
(adipose tissue, platelets, endothelial cells, or erythrocytes). 
Figure 2B:  Summary of metabolic pathways and therapies that modulate cardiac metabolism. 
Natriuretic peptides (ANP and BNP) favor lipolysis and result in an increase in free fatty acids. 
Fatty acids are taken up by the liver and undergo β-oxidation to form ketone bodies (acetoacetate 
and β-hydroxybutyrate). The ketones are transferred to the heart via the bloodstream. In the 
cardiomyocyte, the ketone bodies enter the Krebs cycle and undergo oxidative phosphorylation. 
In cardiomyocytes, acetyl-CoA formed from the ketones limits additional production of acetyl-
CoA from the pyruvate and β-oxidation pathways (dotted arrows). 
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